Type 2 inflammation

Last updated

Type 2 inflammation (or type 2 immunity) is a pattern of immune response. Its physiological function is to defend the body against helminths, but a dysregulation of the type 2 immune response has been implicated in the pathophysiology of several diseases. [1] [2] Although it has traditionally been associated with tumor promotion, emerging evidence indicates a potential tumor-suppressive potential. [3]

Contents

Molecular biology

IL-25, IL-33, and TSLP are alarmins released from damaged epithelial cells. These cytokines mediate the activation of type 2 T helper cells (Th2 cells), group 2 innate lymphoid cells (ILC2 cells), and dendritic cells. Th2 cells and ILC2 cells secrete IL-4, IL-5 and IL-13. [1] [4]

IL-4 further drives CD4+ T cell differentiation towards the Th2 subtype and induces isotype switching to IgE in B cells. IL-4 and IL-13 stimulate trafficking of eosinophils to the site of inflammation, while IL-5 promotes both eosinophil trafficking and production. [2]

Dysregulation in human disease

Type 2 inflammation has been implicated in several chronic diseases:

Persons with one type 2 inflammatory disease are more likely to have other diseases. [10]

Pharmacological targets

Several medicines have been developed that target mediators of type 2 inflammation: [2]

References

  1. 1 2 Allen, Judith E.; Sutherland, Tara E. (2014-08-01). "Host protective roles of type 2 immunity: Parasite killing and tissue repair, flip sides of the same coin". Seminars in Immunology. 26 (4): 329–340. doi:10.1016/j.smim.2014.06.003. ISSN   1044-5323. PMC   4179909 . PMID   25028340.
  2. 1 2 3 Gandhi, Namita A.; Bennett, Brandy L.; Graham, Neil M. H.; Pirozzi, Gianluca; Stahl, Neil; Yancopoulos, George D. (2016-01-01). "Targeting key proximal drivers of type 2 inflammation in disease" . Nature Reviews Drug Discovery. 15 (1): 35–50. doi:10.1038/nrd4624. ISSN   1474-1784. PMID   26471366. S2CID   2421591.
  3. ↑ Wagner, Marek; Nishikawa, Hiroyoshi; Koyasu, Shigeo (January 2025). "Reinventing type 2 immunity in cancer" . Nature. 637 (8045): 296–303. Bibcode:2025Natur.637..296W. doi:10.1038/s41586-024-08194-2. ISSN   1476-4687. PMID   39780006.
  4. ↑ Hong, Haiyu; Liao, Shumin; Chen, Fenghong; Yang, Qintai; Wang, De-Yun (2020). "Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation". Allergy. 75 (11): 2794–2804. doi: 10.1111/all.14526 . ISSN   1398-9995. PMID   32737888. S2CID   220908481.
  5. ↑ Fahy, John V. (2015). "Type 2 inflammation in asthma — present in most, absent in many". Nature Reviews Immunology. 15 (1): 57–65. doi:10.1038/nri3786. ISSN   1474-1733. PMC   4390063 . PMID   25534623.
  6. 1 2 Akdis, Cezmi A.; Arkwright, Peter D.; Brüggen, Marie-Charlotte; Busse, William; Gadina, Massimo; Guttman-Yassky, Emma; Kabashima, Kenji; Mitamura, Yasutaka; Vian, Laura; Wu, Jianni; Palomares, Oscar (2020). "Type 2 immunity in the skin and lungs". Allergy. 75 (7): 1582–1605. doi: 10.1111/all.14318 . ISSN   1398-9995. PMID   32319104. S2CID   216075178.
  7. ↑ Hulse, K. E.; Stevens, W. W.; Tan, B. K.; Schleimer, R. P. (2015). "Pathogenesis of nasal polyposis". Clinical & Experimental Allergy. 45 (2): 328–346. doi:10.1111/cea.12472. PMC   4422388 . PMID   25482020.
  8. ↑ Hill, David A.; Spergel, Jonathan M. (2016). "The Immunologic Mechanisms of Eosinophilic Esophagitis". Current Allergy and Asthma Reports. 16 (2): 9. doi:10.1007/s11882-015-0592-3. ISSN   1529-7322. PMC   4913464 . PMID   26758862.
  9. ↑ Werth, Victoria P.; Murrell, Dédée F.; Joly, Pascal; Heck, Renata; Orengo, Jamie M.; Ardeleanu, Marius; Hultsch, Verena (2024-12-01). "Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)". Advances in Therapy. 41 (12): 4418–4432. doi:10.1007/s12325-024-02992-w. ISSN   1865-8652. PMC   11550233 . PMID   39425892.
  10. ↑ Khan, Asif; Gouia, Imène; Kamat, Siddhesh; Ortiz, Benjamin; Johnson, Robert; Siddall, James; Small, Mark (2020-09-07). "Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis" . European Respiratory Journal. 56 (suppl 64): 232. doi:10.1183/13993003.congress-2020.232. ISSN   0903-1936. S2CID   229017279.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.